Stanford University
Showing 61-80 of 88 Results
-
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Sherril L. Green, DVM, PhD
Professor of Comparative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests: Xenopus laevis. Husbandry, biology, infectious and parasitic diseases of laboratory Xenopus laevis. Large animal models of disease.
-
Tamar Green
Assistant Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences)
Current Research and Scholarly InterestsThe Brain Imaging, Development, and Genetic (BRIDGE) Lab focuses on disorders associated with child development, such as attention deficits, hyperactivity, and autism spectrum disorders. we aim to uncover biological principles of how genetic variation and its associated downstream pathways affect children's neurodevelopmental disorders.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
William Greenleaf
Professor of Genetics
Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.
-
Michael Greicius, MD, MPH
Iqbal Farrukh and Asad Jamal Professor and Professor, by courtesy, of Psychiatry and Behavioral Sciences (Administrative and Academic Special Programs)
Current Research and Scholarly InterestsAs the Medical Director of the Stanford Center for Memory Disorders and Principal Investigator of the Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort, Dr. Greicius' research focuses on elucidating the neurobiologic underpinnings of AD. His lab combines cutting edge brain imaging, "deep" phenotyping, and whole-genome sequencing of human subjects to identify novel pathways involved in AD pathogenesis. The goal of his work is to develop effective treatment for AD patients.
-
Kalanit Grill-Spector
Susan S. and William H. Hindle Professor in the School of Humanities and Sciences
Current Research and Scholarly InterestsFor humans, recognition is a natural, effortless skill that occurs within a few hundreds of milliseconds, yet it is one of the least understood aspects of visual perception. Our research utilizes functional imaging (fMRI),diffusion weighted imaging (DWI), computational techniques, and behavioral methods to investigate the neural mechanisms underlying visual recognition in humans. We also examine the development of these mechanisms from childhood to adulthood as well as between populations.
-
Nicolas Grillet, PhD
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsWe are interested in identifying the genes leading to Hearing and Vestibular impairments, and understanding their function at the molecular level.
We have a special focus on how the Hair Cells are able to detect mechanical stimulation. -
Eric R. Gross
Associate Professor of Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly InterestsA part of the laboratory studies organ injury and how common genetic variants may affect the response to injury caused by surgery; particularly aldehydes. Aldehyde accumulation can cause many post-operative complications that people experience during surgery- whether it be reperfusion injury, post-operative pain, cognitive dysfunction, or nausea. The other part of the lab studies the impact of e-cigarettes and alcohol, when coupled with genetics, on the cardiopulmonary system.
-
James Gross
Ernest R. Hilgard Professor, Professor of Psychology and, by courtesy, of Philosophy
Current Research and Scholarly InterestsI am interested in emotion and emotion regulation. My research employs behavioral, physiological, and brain measures to examine emotion-related personality processes and individual differences. My current interests include emotion coherence, specific emotion regulation strategies (reappraisal, suppression), automatic emotion regulation, and social anxiety.
-
David Grusky
Edward Ames Edmonds Professor of Economics and Senior Fellow at the Stanford Institute for Economic Policy Research
BioDavid B. Grusky is Barbara Kimball Browning Professor in the School of Humanities and Sciences, Director of the Stanford Center on Poverty and Inequality, and coeditor of Pathways Magazine. His research addresses the changing structure of late-industrial inequality and addresses such topics as (a) the role of rent-seeking and market failure in explaining the takeoff in income inequality, (b) the amount of economic and social mobility in the U.S. and other high-inequality countries (with a particular focus on the “Great Gatsby” hypothesis that opportunities for social mobility are declining), (c) the role of essentialism in explaining the persistence of extreme gender inequality, (d) the forces behind recent changes in the amount of face-to-face and online cross-class contact, and (e) the putative decline of big social classes. He is also involved in projects to improve the country’s infrastructure for monitoring poverty, inequality, and mobility by exploiting administrative and other forms of “big data” more aggressively. His recent books include Social Stratification (2014), Occupy the Future (2013), The New Gilded Age (2012), The Great Recession (2011), The Inequality Reader (2011), and The Inequality Puzzle (2010).
-
Anna Grzymala-Busse
Michelle and Kevin Douglas Professor of International Studies and Senior Fellow at the Freeman Spogli Institute for International Studies and, by courtesy, at the Hoover Institution
BioAnna Grzymala-Busse is the Michelle and Kevin Douglas Professor of International Studies in the Department of Political Science, the Director of the Europe Center, and Senior Fellow at the Freeman Spogli Institute. Her research focuses on the historical development of the state and its transformation, political parties, religion and politics, and post-communist politics. Other areas of interest include populism, informal institutions, and causal mechanisms.
She is the author of three books: Redeeming the Communist Past: The Regeneration of Communist Successor Parties; Rebuilding Leviathan: Party Competition and State Development in Post-Communist Europe; Nations Under God: How Churches Use Moral Authority to Influence Politics and Sacred Foundations: the Religious and Medieval Roots of the European State. She is also a recipient of the Carnegie and Guggenheim Fellowships.
